Prescription drug coverage and effective coverage of three chronic conditions of high prevalence in Chile: Hypertension, diabetes and dyslipidemia

• Published in: PloS one 2024-02, Vol.19 (2), p.e0297807-e0297807
• Main Authors: Matute, Isabel, Castillo-Laborde, Carla
• Format: Article
• Language: English
• Subjects: Analysis; Antilipemic agents; Care and treatment; Diabetes; Diagnosis; Drug therapy; Drugs; Dyslipidemias; Earth Sciences; Evaluation; Hydrochlorothiazide; Hypertension; Medicine and Health Sciences; People and places; Prescribing; Prescription drug plans; Prescription writing; Social Sciences; Surveys; Valsartan
• ISSN: 1932-6203; 1932-6203
• DOI: 10.1371/journal.pone.0297807

Access to medicines is a serious problem globally and in Chile. Despite the creation of coverage policies, part of the population with chronic conditions of high prevalence, still does not have access to the medicines it requires and disease control continues to be low. The objective of the study was to estimate the medication use and effective coverage for diabetes, dyslipidemia and hypertension in Chile, analyzing them according to sociodemographic variables and social determinants of health. Cross-sectional analytical study with information from the 2016-2017 National Health Survey (sample = 6,233 people aged 15 years or older, expanded = 14,518,969). Descriptive analyses of medication use and effective coverage for hypertension, diabetes and dyslipidemia were carried out, and multivariate logistic regression models were developed to analyze possible associations with variables of interest. 60% of people with hypertension or diabetes use medications and only 27.7% in dyslipidemia. While 54.2% of those with diabetes have their glycemia controlled, in hypertension and dyslipidemia the effective coverage drops to 33.3% and 6.6%, respectively. There are no differences in use by health system, but there are differences in the control of hypertension and diabetes, favoring beneficiaries of the private subsystem. Effective coverage of dyslipidemia and hypertension also increases in those using medications. The drugs coincide with the established protocols, although beneficiaries of the private sector report greater use of innovative drugs. A significant proportion of Chileans with hypertension, diabetes or dyslipidemia still do not use the required medications and do not control their conditions.